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Background: KOB03 is a polyherbal medicine that originated from the oriental prescription for the treatment of
chronic allergic diseases such as rhinitis and asthma. This study aims to evaluate the effect of KOB03 on ovalbumin
(OVA)-induced allergic rhinitis (AR) in guinea pigs.
Methods: Hartley guinea pigs were sensitized to OVA by intraperitoneal injection on days 0, 7, and 14 and
challenged with intranasal exposure to OVA three times for 7 days after the last sensitization. KOB03 at doses of
200 and 500 mg/kg were orally administrated to guinea pigs once daily during challenge. The serum levels of
histamine, OVA-specific immunoglobulin (Ig) E, eosinophil cationic protein (ECP) and cytokines (TNF-α, IL-4 and
IFN-γ) in OVA sensitization/challenge-induced AR guinea pigs were measured. We also observed histological
changes in nasal tissues of AR guinea pigs by staining with H&E, Periodic acid-Schiff, and toluidine blue.
Results: The administration of KOB03 at a dose of 500 mg/kg significantly decreased the serum levels of histamine
(P = 0.001), OVA-specific IgE (P = 0.0017), ECP (P = 0.008), and TNF-α (P = 0.0003) in OVA-sensitized/challenged guinea
pigs compared with controls. KOB03 significantly decreased the serum levels of a Th2 cytokine, IL-4 (P = 0.017),
while significantly increasing the levels of a Th1 cytokine, IFN-γ (P = 0.0006) in OVA-sensitized/challenged guinea
pigs compared with controls. In addition, KOB03 suppressed the epithelial destruction, goblet cell hyperplasia and
eosinophilic infiltration into nasal mucosa associated with AR.
Conclusion: KOB03 may regulate allergic inflammation in AR by inhibiting nasal damage, the release of allergic
mediators and modulating the balance of Th1/Th2 cytokines.Background
Allergic rhinitis (AR) is an immunoglobulin (Ig) E-
mediated inflammatory disease caused by the inflamma-
tion of airway mucosa with hypersensitivity resulting from
seasonal or perennial responses to specific allergens. It is
characterized by a local influx of eosinophils with clinical
symptoms including nasal rubbing, sneezing, rhinorrhea,
lacrimation, nasal congestion and obstruction [1,2]. AR
also triggers systemic inflammation and is associated with
various co-morbid conditions such as asthma, nasal po-
lyposis, rhinosinusitis, serous otitis media and sleep disor-
ders [3]. The inflammatory response in the nasal mucosa
includes mast cell-mediated allergic responses and a late* Correspondence: yongki@dongguk.ac.kr
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reproduction in any medium, provided the orphase reaction characterized by inflammatory recruitment
of secondary effector cells such as eosinophils, basophils,
and T cells expressing T-helper 2 (Th2) cytokines inclu-
ding interleukin (IL)-4 (a switch factor for IgE synthesis)
and IL-5 (an eosinophil growth factor that promotes aller-
gic inflammation) [4]. In AR, mast cells release inflamma-
tory mediators such as IL-4, IL-5, IL-6, IL-8, IL-12 and
TNF-α when activated by IgE-dependent mechanisms [5].
Basophils and eosinophils are also important for allergic
inflammation and mainly function in the last phase aller-
gic response. T cells are essential for the regulation and
coordination of the adaptive immune response in allergic
disease. Th1 T cells release IL-2 and IFN-γ and are in-
volved in delayed type hypersensitivity whereas Th2 T cells
release IL-4 and IL-5 and mediate IgE-mediated allergic
inflammation [5,6]. Therefore, these cells are considered
as major targets for basic and therapeutic research.
In general, the therapeutic principles for AR treatment
are to avoid allergens/triggering factors, and symptomaticd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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decongestants, cromolyn sodium, leukotriene modifiers,
nasal glucocorticoids, nasal atropine and allergen immu-
notherapy (also known as allergy shots), to reduce an
individual’s sensitivity to the allergen [5]. Although phar-
macotherapy is greatly required, the current treatment for
AR is not ideal, as none of these treatments is sufficiently
efficacious for nasal obstruction when given as monother-
apy [6]. Recently, with a growing global interest in natural
drugs, the search for appropriate anti-allergic agents has
focused on medicinal plants that are traditionally used in
oriental clinics for the treatment of allergic diseases [7].
KOB03 (Table 1) is a polyherbal medicine derived from
the oriental prescription for the treatment of hyperhidro-
sis and allergic diseases such as rhinitis, asthma and itch-
ing [8-11].
This study aims to evaluate the effect of KOB03 on
ovalbumin (OVA) sensitization/challenge-induced AR in




Male Hartley guinea pigs (290–310 g) were purchased
from Samtako Co. Ltd. (Gyeonggido, Republic of Korea).
The animals were housed under controlled environmen-
tal conditions at a temperature of 19–25°C with a re-
lative humidity of 50–60% and 12 h light/dark cycle
throughout the study. The care and treatment of animals
were in accordance with the guidelines established by
the Korean National Institute of Health at the Korean
Academy of Medical Sciences for the care and use of la-
boratory animals and were approved by the Institutional
Animal Care and Use Committee of Dongguk University.
Preparation of KOB03
Herbs used in KOB03 were purchased from the Medi-
cinal Materials Company (Kwangmyungdang Medicinal
Herbs, Ulsan, South Korea). All herbs were authenti-
cated by Professor Y.-K. Park, a medical botanist in the
Department of Herbology, College of Oriental Medi-
cine, Dongguk University (DUCOM), Republic of Korea.
Voucher specimens were deposited in the Herbarium of
the DUCOM under registration number 2011-GMP-
KOB03-11003. Dried extract of KOB was received fromTable 1 Herbal constituents of KOB03
Herbal name Species
Atractylodis Rhizoma Alba Atractylodes japonica Koidz
Astragali Radix Astragalus membranaceus B
Peucedani Japonici Radix Saposhnikovia divaricata Sc
Osterici Radix Ostericum koreanum Maxim
Scutellariae Radix Scutellaria baicalensis GeorgHanpoong Pharm & Food Co., Ltd. (Jeonju, Korea).
Briefly, herbs of KOB03 were mixed according to the
ratios in Table 1, minced with a grinder, extracted with
2000 mL of boiling water (95–100°C) for 4 h, and fil-
tered through 50 μm and 1 μm cartridge paper. The fil-
tered extract was concentrated in a rotary evaporator
(Hanpoong Pharm & Food Co., Ltd., Jeonju, Korea) at
60°C for 15 h with 700 mmHg, and the concentrated ex-
tract was vacuum-dried (yield: 20.0 kg, 40%).
Preparation of AR guinea pig model
The guinea pigs were divided into five groups (n = 10
per group) as follows: normal group, OVA-sensitized/
challenged group as a control, OVA-sensitized/challenged
group with KOB03 at dose of 200 mg/kg or 500 mg/kg,
and OVA-sensitized/challenged group with ketotifen at a
dose of 10 mg/kg as a reference drug. Guinea pigs were
given free access to a standard laboratory diet and water
during the experimental period. OVA solution (1 mg/mL
in saline) and Al(OH)3 (20 mg/mL in saline) were mixed
in a 1 to 1 ratio and then mice were sensitized with an in-
traperitoneal injection on days 0, 7, and 14 (Figure 1). On
the seventh day after the last sensitization, the guinea pigs
were locally challenged by instilling 0.2% OVA solution
(0.04 mL/guinea pig) into the bilateral nasal cavities using
a micropipette three times from day 21 to day 28. KOB03
at a dose of 200 or 500 mg/kg body weight or ketotifen at
a dose of 10 mg/kg body weight, was orally administered
to OVA-sensitized animals once daily for 7 consecutive
days during OVA challenge. Normal and OVA-sensitized/
challenged animals were given saline alone on the same
schedule. Blood samples were taken from each guinea pig
by cardiac puncture under isoflurane anesthesia 24 h after
the oral administration of KOB03. The administrated do-
ses of KOB03 were calculated from the guidelines for the
determination of human equivalent dose (HED) in clinical
applications [12]. Serum was prepared and frozen at −70°C
prior to analysis. The nasal tissues were removed from the
body and histopathological changes were assessed.
Serological analysis
The concentrations of histamine, OVA-specific IgE, eo-
sinophil cationic protein (ECP) and cytokines such as
TNF-α, IL-4, and IFN-γ in the sera of guinea pigs were






Figure 1 Study plan for the development of an experimental in vivo model of AR.
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enzyme immunoassay (EIA) kits (Wuhan EIAAB Science
Co., Ltd.) according to the manufacturer’s recommenda-
tions. The concentration of each substance was calculated
from the equations obtained from standard curve plots for
the standard solutions in the kits.
Histological evaluation of nasal mucosal tissues
Guinea pigs were euthanized with a high dose of isoflur-
ane (1–4%) and exsanguinated after final OVA challenge.
The head was removed and the lower jaw was discarded.
The nasal tissues were separated from the skin, muscle
and soft tissue and immersed in freshly prepared 10%
neutral buffered formalin for 48 h. The tissue was then
rinsed in running tap water and decalcified in 10% nitric
acid solution for 5 days. After rinsing in tap water, the
tissue was processed for dehydration through graded al-
cohol and embedded in paraffin. Serial sections (5 μm)
were cut at the level of the incisive papillae and first and
second palatal ridges and then stained with hematoxylin
and eosin (H&E), Periodic Acid Schiff (PAS) for goblet
cells and Giemsa for eosinophils. Sections were examined
under a light microscope (Leica Microsystems GmbH,
Wetzlar, Germany).
Immunohistochemistry
Specimens were embedded in paraffin, cut into 5-mm-
thick sections and floated onto aminoalkylsilane-coated
slides (Polysciences, PA, USA). The sections were depar-
affinized and rehydrated through graded alcohol washes.
After microwave treatment, the sections were treated
with 0.3% hydrogen peroxide in methanol for 15 min to
inhibit endogenous peroxidase activity of blood cells and
with 1% bovine serum albumin (BSA) in 0.05 M phos-
phate/0.1 M NaCl, pH 7.4 (PBS) containing blocking re-
agent for another 10 min at room temperature. The
sections were incubated with a primary antibody against
TNF-α at the appropriate concentration (1:100) in PBS
with 1% BSA for 12 h or overnight at 4°C. After thor-
ough washing with PBS containing Triton X-100, each
sample was incubated with the secondary antibody (1:100)
in PBS with 1% BSA for 3 h at room temperature. After
repeated washing, the sections were stained with the ABCkit (Dako, Glostrup, Denmark) that includes DAB for
30 min at room temperature. After washing, the sections
were stained with hematoxylin for 1 min (1 drop) at room
temperature. After another wash, the sections were dehy-
drated and mounted with a glass coverslip.High-performance liquid chromatography (HPLC) analysis
HPLC analysis for identification of the standard com-
pounds was performed using an HPLC system (Waters,
MA, USA) equipped with water 510 pump, waters auto-
injector and waters UV/VIS 486 detector. KOB03 powder
(1 g) was dissolved in 10 mL distilled water, extracted with
ultrasonic waves for 5 min, and filtered through a 0.2-μm
PVDF membrane filter. KOB03 (5 mg/mL) or chlorogenic
acid (C16H18O9: 354.31; 4 mg), methylvisamminol gluco-
side (4'-O-beta-D-glucopyranosyl-5-O-methylvisamminol,
C22H28O10: 452.46; 5 mg), calycosin glucoside (calycosin-
7-O-β-D-glucoside, C22H22O10: 446.1; 1 mg), and baicalin
(C21H18O11: 446.37; 21 mg) as standard compounds were
dissolved in 1 mL of 100% methanol for pattern analysis
using HPLC with a photodiode array detector (Waters,
Milford, MA, USA). Chromatographic separation was car-
ried out using an Optimapak C18 (4.6 × 250 mm, 5 μm) at
room temperature. For analysis of chlorogenic acid,
methylvisamminol glucoside, and calycosin glucoside, the
injection volume was 10 μL and the following solvent
ratios were used for the mobile phase with a flow rate of
1.0 mL/min, where solvent A was 0.5% acetic acid in water
and solvent B was 0.5% acetic acid in methanol: 0 min,
25% B; 10 min, 32% B; 20 min, 45% B; 24 min, 48% B;
35 min, 48% B; 40 min, 25% B; and 45 min, 25% B. For
analysis of baicalin, the injection volume was 10 μL and
the following solvent ratios were used for the mobile
phase with a flow rate of 1.0 mL/min, where solvent A
was 1% acetic acid in water and solvent B was 1% acetic
acid in methanol: 0 min, 30% B; 42 min, 65% B; 44 min,
30% B; and 60 min, 30% B. The detection wavelength
(230 nm for chlorogenic acid, methylvisamminol glu-
coside, and calycosin glucoside or 277 nm for baicalin)
was scanned at a flow rate of 1 mL/min at 40°C. The peak
analysis and assignment were performed using the stan-
dard compounds, which were identified in accordance
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chromatogram.
Statistical analysis
Data were expressed as means ± standard deviation (SD).
Statistical significance was analyzed with one-way analysis
of variance (ANOVA), pair-wise and multiple-comparison
testing between groups, as well as the Turkey test using
GraphPad Prism 5.0 software (GraphPad software, Inc.,
CA, USA) followed by Dunnet test for individual compari-




To demonstrate the effect of KOB03 on allergic res-
ponses in vivo, we measured the levels of allergic media-
tors, histamine, OVA-specific IgE, and ECP in the sera
of OVA sensitization/challenge-induced AR guinea pigs.
Sensitization/challenge of OVA in guinea pigs induced
a significant increase in the production of histamine
(Figure 2A; P = 0.0044), OVA-specific IgE (Figure 2B;Figure 2 Effects of KOB03 on the serum levels of allergic mediators in
concentrations of histamine (A), OVA-specific IgE (B), and eosinophil cation
Independent experiments were performed (n = 10 per group) and the data
statistically significant when **P < 0.01 and ***P < 0.001 vs. normal (a) or OVAP = 0.0019) and ECP (Figure 2C; P = 0.0033) compared
with the normal group. The administration of KOB03 at
doses of 200 and 500 mg/kg significantly decreased the
serum levels of histamine (P = 0.003 and P = 0.001, re-
spectively), OVA-specific IgE (P = 0.0005 and P = 0.0017,
respectively) and ECP (P = 0.0016 and P = 0.0008, re-
spectively) compared with the control group. The inhi-
bitory effect of KOB03 on the production of allergic
mediators was similar to those of the ketotifen-adminis-
tered group. These data indicate that KOB03 might have
anti-allergic activity by suppressing the production of al-
lergic mediators in AR.
Th1 and Th2 cytokines
To investigate the effect of KOB03 on the cytokine ba-
lance in vivo, we measured the serum levels of a Th1
cytokine, IFN-γ and a Th2 cytokine, IL-4 by ELISA.
Sensitization/challenge of OVA in guinea pigs signifi-
cantly increased the level of IL-4 (Figure 3A; P = 0.005),
and significantly decreased the level of IFN-γ (Figure 3B;
P = 0.0001) compared with the normal group. The ad-
ministration of KOB03 at doses of 200 and 500 mg/kgOVA sensitization/challenge-induced AR guinea pigs. The
ic protein (ECP) (C) in the sera of guinea pigs were measured by ELISA.
shown indicate the mean ± SD. A difference was considered
-control (b).
Figure 3 Effects of KOB03 on the serum levels of cytokines in OVA sensitization/challenge-induced AR guinea pigs. The concentrations
of IL-4 (A) and IFN-γ (B) in the sera of guinea pigs were measured by ELISA. Independent experiments were performed (n = 10 per group), and
the data shown indicate the mean ± SD. A difference was considered statistically significant when *P < 0.05 **P < 0.01 and ***P < 0.001 vs. normal
(a) or OVA-control (b).
Jung et al. Chinese Medicine 2012, 7:27 Page 5 of 10
http://www.cmjournal.org/content/7/1/27significantly decreased the IL-4 levels (P = 0.0058 and
P = 0.0017, respectively), while significantly increasing
the IFN-γ levels (P = 0.0001 and P = 0.0006, respectively)
compared with the OVA control group. The regulatory
effect of KOB03 on the production of IL-4 and IFN-γ
was superior to that of the ketotifen-treated group.
These data indicate that KOB03 might control the Th1/
Th2 balance in AR.
Histological changes of nasal tissues
Sensitization/challenge of OVA in guinea pigs induced
histological changes in the nasal mucosa such as epithelialFigure 4 Effects of KOB03 on histological changes in the nasal mucos
histological changes of nasal mucosa were observed by microscope after H
nasal epithelial damage with mucosa edema in the OVA-control group (H&
b, OVA control; c, OVA + KOB03 (200 mg/kg)-administrated group; d, OVA +
(10 mg/kg)-administrated group.disruption with mucosa thickening and regional thinning
of the epithelium (Figure 4, H&E), the hyperplasia of
goblet cells containing mucus (Figure 4) and infiltration
of numerous inflammatory cells into the nasal mucosa
(Figure 5). The administration of KOB03 at doses of 200
and 500 mg/kg inhibited the nasal destruction and the
hyperplasia of mucin-producing goblet cells in OVA-sen-
sitized/challenged guinea pigs. Furthermore, the adminis-
tration of KOB03 at a dose of 500 mg/kg significantly
decreased the numbers of infiltrating eosinophils into the
nasal mucosa (P = 0.0092) compared with the OVA con-
trol group. The inhibitory effect of KOB03 on eosinophila of OVA sensitization/challenge-induced AR guinea pigs. The
&E and PAS staining (magnification × 100). The arrows represent
E) and the mucin-positive goblet cells (PAS). a, normal;
KOB03 (500 mg/kg)-administrated group; and e, OVA + ketotifen
Figure 5 Effects of KOB03 on the infiltration of eosinophils into the nasal tissues of OVA sensitization/challenge-induced AR guinea
pigs. (A) The nasal tissues were stained with Giemsa staining (magnification × 100). The arrows represent Giemsa-positive eosinophils infiltrating
the nasal mucosa of guinea pigs. (B) The number of eosinophils in the nasal mucosa was counted by observing the sections under a microscope.
**P < 0.01 vs. normal (a) or OVA-control (b). a, normal; b, OVA control; c, OVA + KOB03 (200 mg/kg)-administrated group; d, OVA + KOB03
(500 mg/kg)-administrated group; and e, OVA + ketotifen (10 mg/kg)-administrated group.
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group. These data indicate that KOB03 might prevent
nasal destruction by allergic inflammation during AR.
TNF-α expression in nasal tissues
To evaluate the effect of KOB03 on allergic inflammation,
we measured the level of TNF-α in the serum of OVA
sensitization/challenge-induced AR guinea pigs by ELISA
(Figure 6A), and determined its expression level in the
nasal mucosa by immunohistochemistry (Figure 6B). Sen-
sitization/challenge of OVA significantly decreased the
level of TNF-α in the sera of guinea pigs (Figure 5A;
P = 0.0007) compared with the normal group. The admin-
istration of KOB03 at doses of 200 and 500 mg/kg signi-
ficantly decreased the level of TNF-α (P = 0.0002 and
P = 0.0003, respectively) in the sera of OVA-sensitized/
challenged guinea pigs compared with the OVA-control
group. In addition, the administration of KOB03 at doses
of 200 and 500 mg/kg remarkably suppressed the expres-
sion of TNF-α in the nasal mucosa and were more effec-
tive for TNF-α inhibition than ketotifen (Figure 5B).
HPLC analysis
In HPLC analysis of KOB03, the peak assignment was
based on the standard compounds, chlorogenic acid,calycosin glucoside, methylvisamminol glucoside, and
baicalin in a HPLC chromatogram. Baicalin was iden-
tified as the main compound of KOB03 (Figure 7A),
and three compounds were also detected in the HPLC
analysis (Figure 7B).
Discussion
Instead of allergen avoidance and environmental control,
manipulation of mediator release from airway epithelial
cells is the main therapeutic target for managing AR. In
addition, treatment strategies have aimed to either re-
duce the effects of mediators from activated cells in
the sensory neural and vascular end organs, or to reduce
the tissue accumulation of activated cells that generate
inflammatory mediators [5,13]. Although second-gene-
ration antihistamines and anticholinergic agents, intra-
nasal corticosteroids and mast cell stabilizers are under
development for pharmacotherapy of allergic diseases
such as asthma and rhinitis, adverse effects and low cli-
nical efficacy remain [1,2].
Traditional medicines, including complementary, alter-
native and herbal medicines that improve multi-factorial
diseases such as allergic diseases, are considered a good
treatment paradigm [14]. KOB03 is a polyherbal medi-
cine derived from herbal prescriptions in oriental clinics,
Figure 6 Effects of KOB03 on TNF-α levels in the serum and in the nasal tissues of OVA sensitization/challenge-induced AR guinea
pigs. (A) The concentration of TNF-α in the sera of guinea pigs was measured by ELISA. Independent experiments were performed (n = 10 per
group), and the data shown indicate the mean ± SD. A difference was considered statistically significant when ***P < 0.001 vs. normal (a) or
OVA-control (b). (B) The expression of TNF-α in the nasal mucosa was observed by immunohistochemistry (magnification × 100). a, normal;
b, OVA control; c, OVA + KOB03 (200 mg/kg)-administrated group; d, OVA + KOB03 (500 mg/kg)-administrated group; and e, OVA + ketotifen
(10 mg/kg)-administrated group.
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inflammatory effects in acute and chronic allergic diseases
[9,10]. We previously reported that the anti-allergic effect
of KOB03 might be due to suppression of mast cell-
mediated allergic inflammation [15]. In the present study,
we verified that KOB03 had a therapeutic effect on allergic
responses in OVA-induced AR in guinea pigs. Among ani-
mal models of allergic diseases such as asthma and rhi-
nitis, the guinea pig model of allergic conjunctivitis has
proved to be a valid model for the assessment of anti-
allergic effects of established and newly developed drugs,
especially those targeting mast cell mediators [16].
Sensitization/challenge of OVA in guinea pigs led to
increases in serum levels of histamine and antigen-
specific IgE and the infiltration of inflammatory cells
such as eosinophils in the epithelium and subepithelium
of the nasal mucosa [5]. Nasal symptoms of AR are
mediated by histamine and inflammatory mediators such
as prostaglandins, leukotrienes, trypase and proinflamma-
tory cytokines secreted from activated mast cells, eosino-
phils and basophils [3,17]. Mast cell-derived mediators
collectively induce acute-phase clinical symptoms by en-
hancing vascular leakage, bronchospasm and activation of
nociceptive neurons linked to parasympathetic reflex [18].In this study, KOB03 markedly inhibited the release of al-
lergic mediators such as histamine and antigen-specific
IgE in OVA-sensitized/challenged guinea pigs. These re-
sults demonstrated that KOB03 could manage allergic
reactions by suppressing mast cell activation in AR similar
to the ketotifen-treated group. Ketotifen is a second-gene-
ration noncompetitive H1-antihistamine and mast cell
stabilizer that helps sufferers of asthma and rhinitis [19].
Eosinophils are inflammatory cells involved in AR [20].
Eosinophils from allergic subjects are primed in vivo
during allergen challenge, and show increased migratory
responses, adhesiveness, degranulation and an altered oxi-
dative mechanism [21,22]. Upon allergen challenge, eosi-
nophils recruited to several organs such as lungs, nose,
skin and eyes, and biological fluids, induce the release
of oxygen radicals, newly generated mediators such as
platelet-activating factor, leukotrienes (LT) C4, and ECP
[21]. Therefore, eosinophils may be responsible for basic
histopathologic changes of target tissues causing vasodila-
tion, mucosal edema, epithelial cell damage, and non-
specific hyperreactivity [23]. ECP is a major basic and po-
tentially cytotoxic granule protein secreted by eosinophils.
In this study, the administration of KOB03 significantly
inhibited the infiltration of eosinophils into the nasal
Figure 7 HPLC pattern analysis of KOB03. (A) HPLC pattern with baicalin. (B) HPLC pattern with chlorogenic acid, calycosin glucoside, and
methylvisamminol glucoside.
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eosinophils after sensitization/challenge of OVA in guinea
pigs. This suggested that KOB03 protected guinea pigs
against allergen-induced allergic immune responses of AR
by suppressing the activation of eosinophils.
The pathogenesis of AR involves the allergen-induced
proliferation of Th2 lymphocytes secreting IL-3, IL-4,
IL-5, IL-9 and IL-13. These cytokines promote IgE pro-
duction, eosinophil activation and mast cell proliferation[24]. During sensitization, antigen processing by antigen-
presenting cells, including dendritic cells, regulates T cell
activation, production of specific cytokines and isotype
switching. Specific IgE production from B cells mediated
by IL-4, is a critical step in the allergic cascade [4,5]. In
the present study, the administration of KOB03 signi-
ficantly inhibited the production of IL-4 in the sera of
OVA-sensitized/challenged guinea pigs and inhibited
the infiltration of inflammatory cells, eosinophils in the
Jung et al. Chinese Medicine 2012, 7:27 Page 9 of 10
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implied that KOB03 might control the imbalance of Th1/
Th2 cytokines in AR. Allergic mucosal inflammation char-
acterized by the tissue infiltration of inflammatory cells
such as eosinophils, basophils, and neutrophils is asso-
ciated with the activation of mast cells and T cells.
Proinflammatory cytokines such as TNF-α and IL-1β
are potent multifunctional cytokines in the pathogenesis
of many inflammatory diseases, including asthma and
rhinitis [25]. These cytokines are produced by a variety
of cells in the airways and are released by the IgE-
dependent activation of mast cells [16]. TNF-α is related
to the pathogenesis of these events by upregulating the
expression of endothelial cell adhesion molecules, mediat-
ing granulocyte chemoattraction, and activating eosino-
phils, mast cells and T cells [26]. Recent studies [27,28]
show that TNF-α may be associated with acquired airway
hyperresponsiveness, a pathophysiological hallmark of al-
lergic and inflammatory diseases and can induce the
transepithelial migration of neutrophils by IL-8 produc-
tion and the upregulation of adhesion molecules. In this
study, administration of KOB03 significantly decreased
the serum level of TNF-α and inhibited its expression in
the nasal mucosa of OVA-sensitized/challenged guinea
pigs. This suggests that KOB03 might suppress allergic in-
flammation by the down-regulation of TNF-α expression
in AR.
KOB03 is a decoction of five herbs with different
pharmacological actions, and the main compound, bai-
calin, has been identified by HPLC analysis as a standard
compound. Baicalin, a flavonoid extracted from various
herbal plants, is reported to have antiallergic properties
in atopic dermatitis [29], type IV allergic reactions [30],
IgE-mediated allergic reactions [31], and anaphylaxis
[32]. In addition, three minor compounds, chlorogenic
acid as a standard compound of Osterici radix, calycosin
glucoside as a standard compound of Astragali radix and
methylvisamminol glucoside as a standard compound of
Saposhnikoviae Radix were also identified in KOB03 by
HPLC analysis. Chlorogenic acid is reported to have an-
tiallergic properties on mast cell-dependent anaphylactic
responses in rats [33]. The ability of KOB03 to control
the allergic inflammatory response in AR was a result of
the synergistic antiallergy and anti-inflammatory effects
of its constituents’ components. Although KOB03 has
therapeutic potential against AR in vivo, further studies
should be conducted to identify the active compounds
of KOB03 and the mechanism of action of the anti-
allergy properties.
Conclusion
The present study demonstrated that KOB03 has thera-
peutic potential in AR by inhibiting nasal obstruction and
the release of inflammatory mediators such as histamine,allergen-specific IgE, and ECP and modulating the im-
balance of Th1/Th2 cytokines in OVA sensitization/
challenge-induced AR guinea pigs. These results suggest
that KOB03 might be developed as a promising natural
medicine for the treatment of allergic rhinitis.
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